Core Viewpoint - The company is disposing of assets through its wholly-owned subsidiary, Qinhuangdao Tangren Pharmaceutical Chain Co., Ltd., by selling land use rights and building ownership for a total price of RMB 24 million [2][10][12]. Group 1: Transaction Overview - The transaction involves the sale of industrial land use rights and building ownership located in Qinhuangdao, with a total estimated transfer price of RMB 24 million [2][10]. - The transaction does not constitute a related party transaction or a major asset restructuring, and it was approved by the board of directors without the need for shareholder approval [3][8][18]. - The decision to close the Qinhuangdao logistics center and consolidate operations at the Hebei Tangshan logistics center is aimed at improving logistics efficiency and cost control [4][7][16]. Group 2: Asset Details - The asset being transferred includes a land use area of approximately 22,999.98 square meters and a building with a total area of 10,691.23 square meters [10][11]. - The assessed value of the building is approximately RMB 14.34 million, while the land use rights are valued at approximately RMB 9.66 million, totaling around RMB 23.99 million [11][12]. Group 3: Financial Impact - The disposal of the asset is expected to enhance asset utilization efficiency and improve the company's financial situation by recovering funds [16][17]. - The transaction is not anticipated to negatively impact the company's financial or operational status, nor will it harm the interests of shareholders [17][18]. Group 4: Transaction Process - The transaction will occur in three phases, with the first phase requiring a 30% deposit of the total price, followed by subsequent payments and the transfer of ownership [12][13][14]. - The final payment is due by November 30, 2025, and the asset transfer is scheduled for August 31, 2025 [13][14].

证券代码：605266 证券简称：健之佳 公告编号：2025-041 健之佳医药连锁集团股份有限公司 关于全资子公司处置资产的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 健之佳医药连锁集团股份有限公司（以下简称"公司"）全资子公司秦皇 岛唐人医药连锁有限责任公司（以下简称"秦皇岛唐人医药"）向自然人赵明女 士出售位于秦皇岛市海港区北部工业区的一宗国有出让工业用地的土地使用权 及其地上建筑物的房屋所有权（以下简称"标的资产"），标的资产转让价格预计 为人民币 2,400 万元整。 本次交易在董事会审批权限内，公司于 2025 年 8 月 18 日召开第六届董 事会第十一次会议审议通过《关于全资子公司处置资产的议案》，无需提交股东 会审议。 一、交易概述 （一）本次交易的基本情况 1、本次交易概况 根据公司省级区域物流配送效率、成本管控原则及模式，各省级分部建立统 一的物流中心负责区域物流配送。 在河北分部，原由唐山原租赁仓库、秦皇岛自有产权仓库两个区域配送中心 实现唐山、秦皇岛区域配送。 公司 ...

Core Viewpoint - The company Jianzhijia (605266) announced the sale of industrial land use rights and associated buildings for a total price of 24 million yuan, which aligns with its business development strategy and aims to improve asset efficiency and control distribution costs [1] Group 1 - The subsidiary Qinhuangdao Tangren Pharmaceutical Chain Co., Ltd. is selling the land use rights and buildings located in the northern industrial area of Qinhuangdao City [1] - The expected transfer price for the assets is 24 million yuan [1] - The disposal of these assets is intended to enhance the company's financial situation by recovering funds [1]

Core Viewpoint - The company Jianzhijia (605266.SH) announced the sale of land use rights and associated buildings in Qinhuangdao for a total price of RMB 24 million [1] Group 1 - The transaction involves the full subsidiary Qinhuangdao Tangren Pharmaceutical Chain Co., Ltd. selling the assets to an individual named Zhao Ming [1] - The assets being sold are located in the northern industrial area of the Haigang District in Qinhuangdao [1] - The expected transfer price for the assets is RMB 24 million [1]

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.01% on August 13, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with the following notable movements: - Seli Medical (603716) rose by 6.55% to a closing price of 31.09, with a trading volume of 556,200 shares and a transaction value of 1.671 billion [1] - Guofa Co. (600538) increased by 1.75% to 6.38, with a trading volume of 129,600 shares [1] - Huaren Health (301408) fell by 1.76% to 15.11, with a trading volume of 179,600 shares and a transaction value of 271 million [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 33.73 million from institutional investors, while retail investors experienced a net outflow of 42.05 million [2] - Notable capital flows for specific stocks included: - Seli Medical had a net inflow of 10.9 million from institutional investors, while retail investors saw a net outflow of 2.46 million [3] - Yiyang Pharmaceutical (301015) had a net inflow of 6.29 million from institutional investors, but retail investors faced a net outflow of 31.02 million [3]

Summary of Key Points Core Viewpoint - The company has signed multiple guarantee contracts to support its wholly-owned subsidiaries in obtaining financing, with a total guarantee amount not exceeding 8 billion RMB, aimed at enhancing operational efficiency and independent business capabilities [1][3][6]. Group 1: Guarantee Agreements - The company has entered into a maximum guarantee contract with Hengfeng Bank for its subsidiary Yunnan Jianzhijia Chain Health Pharmacy, with a maximum debt guarantee amount of 50 million RMB [1]. - A guarantee contract was signed with the Export-Import Bank for the same subsidiary, with a maximum debt guarantee amount of 40 million RMB [2]. - The company has also signed a guarantee contract with Industrial Bank for its subsidiary Guangxi Qinkang, with a maximum debt guarantee amount of 60 million RMB [2]. - A guarantee agreement was made with China Merchants Bank for its subsidiary Sichuan Qinkang, with a maximum guarantee amount of 20 million RMB [2]. Group 2: Internal Decision-Making Process - The company held board meetings and a shareholder meeting to approve the proposal for comprehensive credit limits and guarantees, allowing for a total credit limit of up to 8 billion RMB [3][4]. - The approved credit limit includes 5.5 billion RMB for daily operations and 2.5 billion RMB for specific projects [3]. Group 3: Necessity and Reasonableness of Guarantees - The guarantees are deemed necessary to support the subsidiaries' operational development and financing needs, which will enhance overall financing efficiency and independent operational capabilities [6]. - The company maintains sufficient control over its subsidiaries, allowing for effective monitoring and management of associated risks [6]. Group 4: Board Opinions - The board believes that the guarantees align with the company's development plans and are essential for the subsidiaries' operational funding needs, ensuring smooth business operations [7]. - The guarantees do not involve external parties and are considered manageable in terms of risk [7]. Group 5: Cumulative Guarantee Amounts - As of the announcement date, the total amount of guarantees provided to wholly-owned subsidiaries is 1.913574 billion RMB, representing 68.41% of the company's audited net assets for the year 2024 [8]. - The company has no overdue external guarantees as of the announcement date [9].

Core Viewpoint - The company, Jianzhijia, has announced that it will provide joint liability guarantees for its wholly-owned subsidiaries, with a total guarantee amounting to 191.3574 million yuan, which represents 68.41% of the company's audited net assets for the year 2024 [1][1][1] Summary by Category - **Guarantee Amounts**: The company has provided guarantees for its subsidiaries as follows: 90 million yuan for Yunnan Jianzhijia Chain Health Pharmacy Co., Ltd., 60 million yuan for Guangxi Jianzhijia Qinkang Pharmaceutical Sales Co., Ltd., and 20 million yuan for Sichuan Qinkang Jianzhijia Pharmaceutical Co., Ltd. [1][1][1] - **Impact on Financials**: The total amount of guarantees provided by the company to its subsidiaries is 191.3574 million yuan, which constitutes 68.41% of the company's audited net assets for the fiscal year 2024 [1][1][1]

证券代码：605266 证券简称：健之佳 公告编号：2025-040 健之佳医药连锁集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 担 保 | 对 | 被担保人名称 | | | 云南健之佳连锁健康药房有限公司 | | --- | --- | --- | --- | --- | --- | | | | 本次担保金额 | 9,000.00 | 万元 | | | 象一 | | 实际为其提供的担保余额 | 65,119.74 | 万元 | | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | | 本次担保是否有反担保 | □是 | ☑否 | □不适用：_________ | | 担 保 | 对 | 被担保人名称 | | | 广西健之佳勤康医药销售有限公司 | | | | 本次担保金额 | 6,000.00 | 万元 | | | 象二 | | 实际为其提供的担保余额 | 7,570.82 | 万元 ...

Core Insights - The retail pharmacy industry in China is experiencing a significant downturn, with an estimated 39,000 pharmacies expected to close in 2024, averaging 107 closures per day, and projections suggesting that closures could exceed 100,000 by 2025 [1][2] - Major players in the industry, such as Guoda Pharmacy and Jianzhijia, have reported substantial losses, with Guoda closing over 1,270 stores and incurring a net loss of over 1.1 billion yuan in 2024 [2] - The rapid expansion of pharmacies from 524,000 in 2019 to 667,000 in 2023 has led to market saturation, with the average number of customers served per store dropping from 4,112 in 2016 to 2,113 in 2023 [2][3] Industry Challenges - The high density of pharmacies has resulted in aggressive price competition, with many stores resorting to loss-leader pricing strategies to attract customers, ultimately harming their profitability [3] - Changing consumer habits, particularly among younger generations who prefer online channels for purchasing medications, have further exacerbated the decline in foot traffic to physical stores [3] - Tightening healthcare policies, including stricter regulations on insurance reimbursements and the shift of chronic disease medication distribution from pharmacies to community hospitals, have significantly impacted pharmacy revenues [3][4] Regulatory Environment - Starting in 2025, all participating pharmacies must implement drug traceability codes, complicating the procurement and settlement processes, which could increase operational costs for smaller pharmacies [4][5] - The requirement for licensed pharmacists to be present in all pharmacies by December 31, 2025, adds further compliance pressure, particularly for smaller operations [5] - The transition from a rapid expansion phase to a necessary industry adjustment reflects the need for pharmacies to focus on their role in public health rather than profit maximization [5]

Group 1 - The overall market size of retail pharmacies in China reached 923.3 billion yuan in 2023, with a CAGR of 7.7% from 2019 to 2023 [1][6] - The number of retail pharmacies has been continuously increasing, totaling 667,000 in 2023, with an average service population per store of approximately 2,114, which is declining [1][6] - The online pharmacy segment has shown significant growth, contributing 78% to the overall sales growth of pharmacies in 2023, with online sales accounting for 33% of total pharmacy sales [9][10] Group 2 - The retail pharmacy market in Yunnan is characterized by high concentration and regional imbalance, with a chain rate of 57.16% [1][23] - Local chain enterprises like Yixin Tang and Jianzhijia are leveraging local resources for deep penetration and are expected to accelerate their expansion outside the province [1][27] - The expansion of Yunnan's leading pharmacy chains outside the province is evident, with Yixin Tang's share of in-province stores decreasing from 59.46% in 2020 to 48.49% in 2024 [27][28] Group 3 - The importance of retail pharmacies has been increasing due to various policies promoting the separation of medicine and healthcare, with the pharmacy channel expected to see accelerated prescription sales [2][29] - The implementation of outpatient coordination is crucial for reducing unnecessary hospital resource occupation and enhancing patient convenience [2][39] - The expected increase in prescription outflow could lead to a market increment of over 1 billion yuan from 2025 to 2027 [2][59] Group 4 - Companies that excel in professional services, diversified operations, and omnichannel strategies are likely to achieve better competitive differentiation and find new growth avenues [3][65] - The online sales channel is becoming increasingly important, with O2O sales expected to rise significantly, potentially reaching 1,444 billion yuan by 2030 [66] - The development of self-owned brands and non-pharmaceutical products can help pharmacies reduce reliance on insurance funds and improve profit margins [62][64]